Since the breakthrough made in gene recombination technique and deeper understanding on mechanism of tumorigenesis,immunotherapy has moved into the mainstream of oncology treatment.Chimeric antigen receptor(CAR)T cell adoptive immunotherapy has become a promising therapy for cancer.Early clinical trials using CAR T cells for the treatment of patients with refractory hematological malignancies achieved promising efficacy.Despite these wonderful clinical outcome,there still exist many patients could’d get continuous remission or show no response to CAR-T therapy and responses among patients with multiple myeloma or refractory and relapsed acute myeloid leukemia haven’t win great satisfaction.Additionally,cytokine release syndrome is the most significant and life-threatening toxicity which needs more clinical experiences.All above may guide new challenges and important discoveries in immunotherapy of hematological malignancies.